William J. Ferenczy Net Worth

The estimated Net Worth of William J. Ferenczy is at least $1.34 Million dollars as of 12 June 2021. William Ferenczy owns over 2,000 units of QuidelOrtho stock worth over $328,481 and over the last 4 years William sold QDEL stock worth over $1,006,844.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

William Ferenczy QDEL stock SEC Form 4 insiders trading

William has made over 4 trades of the QuidelOrtho stock since 2021, according to the Form 4 filled with the SEC. Most recently William exercised 2,000 units of QDEL stock worth $89,700 on 12 June 2021.

The largest trade William's ever made was selling 7,400 units of QuidelOrtho stock on 17 March 2021 worth over $1,006,844. On average, William trades about 818 units every 7 days since 2021. As of 12 June 2021 William still owns at least 7,324 units of QuidelOrtho stock.

You can see the complete history of William Ferenczy stock trades at the bottom of the page.

Insiders trading at QuidelOrtho

Over the last 21 years, insiders at QuidelOrtho have traded over $509,235,797 worth of QuidelOrtho stock and bought 304,015 units worth $10,385,234 . The most active insiders traders include Jack W Schuler, Matthew Strobeck, and Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of $1,246,606. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth $3,078,785.

What does QuidelOrtho do?

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

Complete history of William Ferenczy stock trades at QuidelOrtho

QuidelOrtho executives and stock owners

QuidelOrtho executives and other stock owners filed with the SEC include:

• Douglas Bryant,
  President, Chief Executive Officer, Director
• Douglas C. Bryant,
  Pres, CEO & Director
• Randall Steward,
  Chief Financial Officer
• Michael Abney,
  Senior Vice President - Distribution
• Robert Bujarski,
  Chief Operating Officer
• Ratan Borkar,
  Senior Vice President - International Commercial Operations
• Werner Kroll,
  Senior Vice President - R&D
• Edward Russell,
  Senior Vice President - Business Development
• Robert J. Bujarski,
  Chief Operating Officer
• Randall J. Steward,
  Chief Financial Officer
• Dr. Werner Kroll,
  Sr. VP of R&D
• Ratan S. Borkar,
  Sr. VP of International Commercial Operations
• Robert J. Bujarski J.D.,
  Pres & COO
• Kenneth Buechler,
  Independent Chairman of the Board
• Edward Michael,
  Independent Director
• Ken Widder,
  Independent Director
• Charles Slacik,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Mary Polan,
  Independent Director
• Kathy Ordonez,
  Independent Director
• Ruben Argueta,
  Director - Investor Relations
• Ann Rhoads,
  Director
• Karen Gibson,
  Senior Vice President, Information Systems and Business Transformation
• Dr. Chockalingam Palaniappan Ph.D.,
  Chief Innovation Officer
• Patrick E. Klein,
  Chief Admin. Officer
• Louise Brandy,
  Chief Information Officer
• Rhys de Callier,
  VP of Strategy & Portfolio Management
• Dr. Johannes Kehle,
  Pres of AnDiaTec Division
• Phillip S. Askim,
  VP, Associate Gen. Counsel & Sec.
• Michael S. Iskra,
  Chief Commercial Officer
• Joseph M. Busky CPA,
  Chief Financial Officer
• Karen C. Gibson,
  Sr. VP of Digital Health Bus. Unit
• Edward Keith Russell,
  Sr. VP of Bus. Devel.
• Michael Donald Abney Jr.,
  Sr. VP of North American Sales & Distribution
• Michelle A. Hodges,
  Sr. VP & Gen. Counsel
• Group Inc.Carlyle Holdings ...,
  
• Thomas D Brown,
  Director
• Rodney F Dammeyer,
  Director
• John Tamerius,
  Sr. VP - Clinical/Reg Affairs
• Patrick Klein,
  Chief Administrative Officer
• Louise Brandy,
  SVP, Chief Information Officer
• Tamara A. Ranalli,
  SVP, Molecular Bus. Unit
• Mark W Smits,
  SVP-Commercial Operations
• Mark Pulido,
  Director
• John Matthew Radak,
  Chief Financial Officer
• Timothy Todd Stenzel,
  Chief Science Officer
• Scot M Mc Leod,
  Sr. VP - Operations
• Caren L Mason,
  President and CEO
• Jack W Schuler,
  Director
• Thomas James Foley,
  Chief Technical Officer
• David R. Scholl,
  Senior Vice President
• Richard C Iii Tarbox,
  Sr. VP - Corporate Development
• Matthew T Heindel,
  Sr. VP - Global Sales & Mrktg
• Douglas S Harrington,
  Director
• Faye Wattleton,
  Director
• Mark Paiz,
  Senior Vice President
• Thomas A Glaze,
  Director
• Paul E Landers,
  Sr. V.P., CFO and Secretary
• S Wayne Kay,
  President & CEO
• William J. Ferenczy,
  SVP, Cardio/Metabolic Unit
• Michael S. Iskra,
  EVP & CCO
• Christopher M Smith,
  Director
• Joseph D Jr. Wilkins,
  
• Evelyn S Dilsaver,
  
• Joseph M Busky,
  Chief Financial Officer
• James Prutow,
  
• Michelle A. Hodges,
  SVP, General Counsel